The NanoPortal implant design is simple, elegant, and space-efficient. The passive delivery mechanism eliminates the additional components and failure modes present in mechanical alternatives. The small device size enables implantation by syringe needle, resulting in a quick and easy outpatient procedure.
Made predominantly from titanium and titania, the adhesive-free NanoPortal implant is optimized for biocompatibility. The NanoPortal implant is in preclinical development and is currently not used in any human studies or clinics.
The Whole Package
And Nothing But The Package
A hermetic seal is created without any adhesives, producing a predominantly titanium/titania device.
The NanoPortal membrane is attached at the end of a drug-filled titanium reservoir such that the only exit path for the therapeutics is through the nanotubes.
More Drug, Less Space
Since the rate-limiting function of the device is accomplished by the thin NanoPortal membrane, the remaining space consists entirely of medication.
With the majority of the device devoted to drug, extended treatment durations can be achieved by a small device.
Adjustable reservoir dimensions
Easily-adjusted device lengths and diameters permit customization to accommodate a variety of constraints.
Higher potency formulations maximize treatment duration from smaller devices.
Devices can be designed to incorporate more than 300 mg of medication, depending on device size and formulation concentration.